M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Cellceutix Corporation to commence clinical study of anti-psoriasis drug Prurisol and upgrade to national securities exchange
Biopharmaceutical company Cellceutix Corporation (OTCBB:CTIX) announced on Monday that it is on track to begin a clinical study for its anti-psoriasis drug Prurisol upon completion of all regulatory documents.
The company anticipates that it will receive the regulatory documents this week,...
If you want to view the full text, you must first purchase archive credits.
Return to Archives